Located in Tewksbury, Massachusetts, Cambridge Heart has quickly earned its reputation as a developer of non-invasive diagnostic tests for cardiac disease. Today, the company took a major step towards prominence with the announcement they have reached an agreement for the distribution of their HearTwave II System in Singapore.
Cambridge Heart executed the exclusive agreement with EO Medical. EO Medical is a leading supplier of state-of-the-art medical devices to healthcare providers across the globe.
Leading the way at Cambridge Heart is Ali Haghighi-Mood whom serves as the company’s CEO. Haghighi-Mood commented, “This is a great opportunity for the Company that will incrementally add to our global presence. We look forward to gaining regulatory approval in Singapore, which we expect will occur within the next six to nine months, and begin marketing our MTW technology.”
Sudden Cardiac Arrest (SCA) is a leading cause of death throughout the United States and accounts for an estimated 300,000 deaths each year. Cambridge Heart has placed their business at the forefront in fighting this statistic.
Currently, Cambridge Heart is trading in the $0.17 range. To learn more about Cambridge Heart, Inc. as a whole, visit their corporate website at www.cambridgeheart.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment